AMAG Pharmaceuticals, Inc. (AMAG) Posts Narrower than Expected Q3 Loss; CEO Pereira Resigns
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Price: $13.75 --0%
Financial Fact:
License fee and other collaboration revenues: 40K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
License fee and other collaboration revenues: 40K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported Q3 EPS of ($0.78), $0.22 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $16.22 million.
AMAG announced today that Dr. Pereira has resigned from his position as president, CEO and a director of the company, effective immediately. Dr. Pereira will remain a key strategic advisor to the company on certain matters, including the ongoing development and regulatory work related to its broad phase III program for patients with iron deficiency anemia (IDA). AMAG also announced the departure of Gary Zieziula, the company’s chief commercial officer, effective immediately.
AMAG announced today that Dr. Pereira has resigned from his position as president, CEO and a director of the company, effective immediately. Dr. Pereira will remain a key strategic advisor to the company on certain matters, including the ongoing development and regulatory work related to its broad phase III program for patients with iron deficiency anemia (IDA). AMAG also announced the departure of Gary Zieziula, the company’s chief commercial officer, effective immediately.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Prenetics Global (PRE) Tops Q2 EPS by 18c
Create E-mail Alert Related Categories
Earnings, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
